Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 15-Minute test stop a deadly virus in its tracks?

NCT ID NCT06894758

Diagnosis Sponsor: Liverpool School of Tropical Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial evaluates a new rapid diagnostic test designed to detect Crimean-Congo hemorrhagic fever (CCHF) at the point of care. The test aims to provide results in minutes instead of the current 2-5 days, which could speed up treatment and reduce the risk of the disease spreading. Researchers will test the device using 200 fresh blood samples from patients in Turkey during the 2025 CCHF season. If the test meets World Health Organization standards, a larger clinical trial will follow to support regulatory approval.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A rapid diagnostic test (RDT) prototype that detects Crimean-Congo hemorrhagic fever viral antigens in blood samples.
What this could lead to
If the test proves accurate, it could enable fast, on-the-spot diagnosis of Crimean-Congo hemorrhagic fever, allowing earlier treatment and reducing the spread of the disease.
What could go wrong
The test is still in early development, and this study is relatively small. It may not meet the accuracy standards needed for regulatory approval, and its performance with fresh samples is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

196 people

The number who actually took part.

Started

Jun 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants suspected of CCHF infection requiring a standard of care test.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing to give whole blood samples (in a serum tube and EDTA tube) suspected of CCHF from Türkiye, Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Sivas Cumhuriyet University, Sivas or the department of Infectious Diseases or Ondokuz Mayis University (OMU) Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Samsun, that have not been frozen or refrigerated. 2. Adults aged 18 or over. Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crimean-congo haemorrhagic fever are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Communicable Diseases, Emerging Crimean-Congo hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infectious diseases, emerging

Contacts and locations

Locations

  • Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Sivas Cumhuriyet University, Sivas

    Sivas, 58000, Turkey (Türkiye)

  • Ondokuz Mayis University (OMU) Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Samsun

    Samsun, 55200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.